These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35890180)

  • 41. Dupilumab in Elderly Patients With Severe Atopic Dermatitis.
    Russo F; Milanesi N; Cartocci A; Bruzziches F; Tronconi G; Lazzeri L; D'erme AM; Bagnoni G; Gola M; Cinotti E; Rubegni P; Flori ML
    Dermatitis; 2021 Oct; 32(1S):S24-S27. PubMed ID: 33332865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.
    Tsianakas A; Luger TA; Radin A
    Br J Dermatol; 2018 Feb; 178(2):406-414. PubMed ID: 28845523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: An observational study.
    Cristaudo A; Pigliacelli F; Sperati F; Orsini D; Cameli N; Morrone A; Mariano M
    Skin Res Technol; 2021 Sep; 27(5):810-813. PubMed ID: 33651467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
    Fang HY; Lian CH
    J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The ability of biomarkers to assess the severity of atopic dermatitis.
    Nakahara T; Onozuka D; Nunomura S; Saeki H; Takenaka M; Matsumoto M; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Saito R; Okano T; Miyagaki T; Aoki N; Nakajima K; Ichiyama S; Kido-Nakahara M; Tonomura K; Nakagawa Y; Tamagawa-Mineoka R; Masuda K; Takeichi T; Akiyama M; Ishiuji Y; Katsuta M; Kinoshita Y; Tateishi C; Yamamoto A; Morita A; Matsuda-Hirose H; Hatano Y; Kawasaki H; Fukushima-Nomura A; Ohtsuki M; Kamiya K; Kabata Y; Abe R; Mitsui H; Kawamura T; Tsuji G; Katoh N; Furue M; Izuhara K
    J Allergy Clin Immunol Glob; 2024 Feb; 3(1):100175. PubMed ID: 37915726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response.
    Lee Y; Kim ME; Nahm DH
    Allergy Asthma Immunol Res; 2021 Sep; 13(5):733-745. PubMed ID: 34486258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Higher baseline serum lactate dehydrogenase level is associated with poor effectiveness of dupilumab in the long term in patients with atopic dermatitis.
    Kato A; Kamata M; Ito M; Uchida H; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2020 Sep; 47(9):1013-1019. PubMed ID: 32548920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
    Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
    Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
    Reich K; Lio PA; Bissonnette R; Alexis AF; Lebwohl MG; Pink AE; Kabashima K; Boguniewicz M; Nowicki RJ; Valdez H; Zhang F; DiBonaventura M; Cameron MC; Clibborn C
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3228-3237.e2. PubMed ID: 36108923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validity and reliability of Patient-Reported Outcomes Measurement Information System Global Health scale in adults with atopic dermatitis.
    Schwartzman G; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY; Silverberg JI
    J Am Acad Dermatol; 2021 Sep; 85(3):636-644. PubMed ID: 33484762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab.
    Mizuno M; Horiguchi G; Teramukai S; Ichiyama S; Ito M; Hoashi T; Kanda N; Saeki H
    Australas J Dermatol; 2021 Nov; 62(4):e504-e509. PubMed ID: 34523731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validation of four single-item patient-reported assessments of sleep in adult atopic dermatitis patients.
    Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Sacotte R; Patel KR; Singam V; Immaneni S; Kantor R; Hsu DY; Silverberg JI
    Ann Allergy Asthma Immunol; 2020 Mar; 124(3):261-266. PubMed ID: 31830585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study.
    Torres T; Cruz MJ; Gonçalo M; Filipe P; Duarte B; Alves J; Alvarenga JM; Rosa G; Flor D; Ramos J; Sousa D; Rosca A; Magalhães C; Claro C; Rocha J; Vilarinho C; Mota F; Mota A; Lopes MJP
    Dermatol Ther (Heidelb); 2024 Aug; 14(8):2209-2221. PubMed ID: 39039360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.
    Heratizadeh A; Haufe E; Stölzl D; Abraham S; Heinrich L; Kleinheinz A; Wollenberg A; Weisshaar E; Augustin M; Wiemers F; Zink A; von Kiedrowski R; Hilgers M; Worm M; Pawlak M; Sticherling M; Fell I; Handrick C; Schäkel K; Staubach-Renz P; Asmussen A; Schwarz B; Bell M; Effendy I; Bieber T; Homey B; Gerlach B; Tchitcherina E; Stahl M; Schwichtenberg U; Rossbacher J; Buck P; Mempel M; Beissert S; Biedermann T; Weidinger S; Schmitt J; Werfel T;
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1263-1272. PubMed ID: 31721316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
    Napolitano M; Maffei M; Patruno C; Leone CA; Di Guida A; Potestio L; Scalvenzi M; Fabbrocini G
    Dermatol Ther; 2021 Nov; 34(6):e15120. PubMed ID: 34472171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
    Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V
    J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.
    Tánczosová M; Kojanová M; Arenbergerová M; Arenberger P; Doležal T; Štrosová D; Fialová J; Gkalpakiotis S
    Cent Eur J Public Health; 2022 Mar; 30(1):46-50. PubMed ID: 35421298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
    Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
    Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.